Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Chembio Diagnostics, Inc. (CEMI : NSDQ)
 
 • Company Description   
CHEMBIO DIAGNOSTICS, INC. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by a third party company. Chembio markets its HIV STAT-PAK line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and chagas disease. In 2007 Chembio received a U.S. patent for its Dual Path Platform technology which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP. Chembio is licensed by the U.S. Food and Drug Administration as well as the U. S. Department of Agriculture, and is certified for the global market under the International Standards Organization directive 13.485.

Number of Employees: 337

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.64 Daily Weekly Monthly
20 Day Moving Average: 197,794 shares
Shares Outstanding: 30.22 (millions)
Market Capitalization: $19.34 (millions)
Beta: 1.73
52 Week High: $7.34
52 Week Low: $0.42
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -7.38% 4.31%
12 Week -31.37% -24.56%
Year To Date -43.86% -29.54%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
555 WIRELESS BLVD.
-
HAUPPAUGE,NY 11788
USA
ph: 631-924-1135
fax: 631-924-2065
investor@chembio.com https://chembio.com
 
 • General Corporate Information   
Officers
Richard L. Eberly - Chief Executive Officer and President
Katherine L. Davis - Chair of the Board
Lawrence J. Steenvoorden - Chief Financial Officer
David W. K. Acheson - Director
David W. Bespalko - Director

Peer Information
Chembio Diagnostics, Inc. (BJCT)
Chembio Diagnostics, Inc. (CADMQ)
Chembio Diagnostics, Inc. (APNO)
Chembio Diagnostics, Inc. (UPDC)
Chembio Diagnostics, Inc. (IMTIQ)
Chembio Diagnostics, Inc. (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 163572209
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 30.22
Most Recent Split Date: 5.00 (0.13:1)
Beta: 1.73
Market Capitalization: $19.34 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.73
Price/Cash Flow: -
Price / Sales: 0.33
EPS Growth
vs. Year Ago Period: -31.82%
vs. Previous Quarter: 9.38%
Sales Growth
vs. Year Ago Period: 115.69%
vs. Previous Quarter: -8.54%
ROE
03/31/22 - -100.75
12/31/21 - -89.24
09/30/21 - -86.50
ROA
03/31/22 - -46.25
12/31/21 - -40.71
09/30/21 - -38.56
Current Ratio
03/31/22 - 3.54
12/31/21 - 3.59
09/30/21 - 5.32
Quick Ratio
03/31/22 - 2.67
12/31/21 - 2.74
09/30/21 - 3.85
Operating Margin
03/31/22 - -53.86
12/31/21 - -56.25
09/30/21 - -65.84
Net Margin
03/31/22 - -65.95
12/31/21 - -70.90
09/30/21 - -72.24
Pre-Tax Margin
03/31/22 - -65.93
12/31/21 - -71.03
09/30/21 - -72.79
Book Value
03/31/22 - 0.88
12/31/21 - 1.14
09/30/21 - 1.59
Inventory Turnover
03/31/22 - 3.22
12/31/21 - 2.29
09/30/21 - 1.46
Debt-to-Equity
03/31/22 - 0.64
12/31/21 - 0.52
09/30/21 - 0.39
Debt-to-Capital
03/31/22 - 39.03
12/31/21 - 34.10
09/30/21 - 27.84
 

Powered by Zacks Investment Research ©